Cargando…
Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
Chimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for refractory and relapsed leukemia patients and is also emerging as a potential therapeutic option in solid tumors. Viral vector-based CAR T-cells initially drove these successful efforts; however, high costs and c...
Autores principales: | Magnani, Chiara F., Tettamanti, Sarah, Alberti, Gaia, Pisani, Ilaria, Biondi, Andrea, Serafini, Marta, Gaipa, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349235/ https://www.ncbi.nlm.nih.gov/pubmed/32471151 http://dx.doi.org/10.3390/cells9061337 |
Ejemplares similares
-
Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023) -
Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go
por: Puiggros, Anna, et al.
Publicado: (2014) -
Acute childhood leukemia in India: Where are we going, where have we been?
por: Kanwar, Vikramjit Singh
Publicado: (2016) -
P1361: SLEEPING BEAUTY PLATFORM FOR ENGINEERING CAR-CIK CELLS TOWARD A MULTI-TARGETING STRATEGY IN B-ALL
por: Moretti, Alex, et al.
Publicado: (2023) -
Drugs for improving esophageal mucosa defense: where are we now and where are we going?
por: Savarino, Edoardo, et al.
Publicado: (2017)